Eric Polley to Antineoplastic Agents
This is a "connection" page, showing publications Eric Polley has written about Antineoplastic Agents.
Connection Strength
0.695
-
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. J Natl Cancer Inst. 2016 10; 108(10).
Score: 0.251
-
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. Mol Cancer Ther. 2023 Nov 01; 22(11):1270-1279.
Score: 0.105
-
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol. 2021; 5.
Score: 0.086
-
Clinical Activity of the ?-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 May 10; 35(14):1561-1569.
Score: 0.066
-
Association of ?H2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer. Theranostics. 2017; 7(4):945-951.
Score: 0.066
-
Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Lett. 2016 Feb 28; 371(2):225-39.
Score: 0.061
-
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. Cancer Res. 2018 12 15; 78(24):6807-6817.
Score: 0.019
-
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016 Apr; 45:87-96.
Score: 0.015
-
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013 Jul 15; 73(14):4372-82.
Score: 0.013
-
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20; 31(18):2296-302.
Score: 0.013